{"nctId":"NCT02636946","briefTitle":"A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension","startDateStruct":{"date":"2016-02-24","type":"ACTUAL"},"conditions":["Glaucoma","Open-Angle Ocular Hypertension"],"count":144,"armGroups":[{"label":"SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bimatoprost SR","Drug: Sham Bimatoprost SR","Procedure: Selective Laser Trabeculoplasty","Procedure: Sham Selective Laser Trabeculoplasty"]},{"label":"Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye)","type":"EXPERIMENTAL","interventionNames":["Drug: Bimatoprost SR","Drug: Sham Bimatoprost SR","Procedure: Selective Laser Trabeculoplasty","Procedure: Sham Selective Laser Trabeculoplasty"]}],"interventions":[{"name":"Bimatoprost SR","otherNames":[]},{"name":"Sham Bimatoprost SR","otherNames":[]},{"name":"Selective Laser Trabeculoplasty","otherNames":[]},{"name":"Sham Selective Laser Trabeculoplasty","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- Diagnosis of either Open-Angle Glaucoma or Ocular Hypertension in each eye that require IOP lowering treatment.\n\nExclusion Criteria:\n\n* Eye surgery (including cataract surgery) and or eye laser surgery within the past 6 months.\n* Enrollment in other studies using Bimatoprost SR.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Intraocular Pressure (IOP) at Baseline","description":"IOP is a measurement of the fluid pressure inside the eye. Measurements were taken at Hour 0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.45","spread":"2.75"},{"groupId":"OG001","value":"24.38","spread":"2.49"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in IOP at Week 4","description":"IOP is a measurement of the fluid pressure inside the eye. Measurements were taken at Hour 0. A negative change from Baseline indicates an improvement and a positive change from Baseline indicates a worsening. A mixed-effects model with repeated measures (MMRM) was used for analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.28","spread":"0.30"},{"groupId":"OG001","value":"-6.98","spread":"0.29"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in IOP at Week 12","description":"IOP is a measurement of the fluid pressure inside the eye. Measurements were taken at Hour 0. A negative change from Baseline indicates an improvement and a positive change from Baseline indicates a worsening. A MMRM was used for analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.28","spread":"0.29"},{"groupId":"OG001","value":"-6.81","spread":"0.29"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Intraocular Pressure (IOP) at Week 24","description":"IOP is a measurement of the fluid pressure inside the eye. Measurements were taken at Hour 0. A negative change from Baseline indicates an improvement and a positive change from Baseline indicates a worsening. A MMRM was used for analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.34","spread":"0.29"},{"groupId":"OG001","value":"-6.59","spread":"0.29"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in IOP at Weeks 8, 15, and 20","description":"IOP is a measurement of the fluid pressure inside the eye. Measurements were taken at Hour 0. A negative change from Baseline indicates an improvement and a positive change from Baseline indicates a worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.65","spread":"3.10"},{"groupId":"OG001","value":"-7.09","spread":"2.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.14","spread":"3.47"},{"groupId":"OG001","value":"-5.36","spread":"3.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.06","spread":"3.33"},{"groupId":"OG001","value":"-4.29","spread":"1.93"}]}]}]},{"type":"SECONDARY","title":"Time to Initial Use of Nonstudy IOP-lowering Treatment as Determined by the Investigator","description":"Median time in days from first treatment to the initial use of non-study IOP-lowering treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"410","spread":null},{"groupId":"OG001","value":"446","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Eyes Achieving a ≥ 20% Reduction in IOP","description":"IOP is a measurement of the fluid pressure inside the eye. Measurements were taken at Hour 0. The participants who did not continue in the subsequent cycle were followed up to Week 52 in Cycle 1, Week 36 in Cycle 2, and Week 20 in Cycle 3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.6","spread":null},{"groupId":"OG001","value":"92.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.2","spread":null},{"groupId":"OG001","value":"78.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","spread":null},{"groupId":"OG001","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.9","spread":null},{"groupId":"OG001","value":"75.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.2","spread":null},{"groupId":"OG001","value":"64.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null},{"groupId":"OG001","value":"45.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null},{"groupId":"OG001","value":"45.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.7","spread":null},{"groupId":"OG001","value":"72.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","spread":null},{"groupId":"OG001","value":"54.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null},{"groupId":"OG001","value":"45.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.7","spread":null},{"groupId":"OG001","value":"54.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null},{"groupId":"OG001","value":"81.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.2","spread":null},{"groupId":"OG001","value":"89.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":null},{"groupId":"OG001","value":"75.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","spread":null},{"groupId":"OG001","value":"71.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.0","spread":null},{"groupId":"OG001","value":"65.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.4","spread":null},{"groupId":"OG001","value":"64.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","spread":null},{"groupId":"OG001","value":"64.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.4","spread":null},{"groupId":"OG001","value":"71.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.5","spread":null},{"groupId":"OG001","value":"74.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.7","spread":null},{"groupId":"OG001","value":"74.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.1","spread":null},{"groupId":"OG001","value":"67.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","spread":null},{"groupId":"OG001","value":"90.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.2","spread":null},{"groupId":"OG001","value":"71.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"59.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","spread":null},{"groupId":"OG001","value":"43.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.7","spread":null},{"groupId":"OG001","value":"39.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":72},"commonTop":["Conjunctival hyperaemia","Intraocular pressure increased","Punctate keratitis","Corneal endothelial cell loss","Corneal oedema"]}}}